Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Director | July 12, 2023 | July 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mineralys Therapeutics, Inc.
Report date July 12, 2023 · Filed July 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2033-02-09 | Direct | 0 |
Reported balance
After 2023-07-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-12 · Other · Disposed 44,000 · Balance 0 F1: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. F2: The stock option vests in 36 monthly installments beginning on March 9, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.
F2: The stock option vests in 36 monthly installments beginning on March 9, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 12, 2023 Filed Jul 14, 2023 12:55 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherStock Option · Derivative | 44,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001933414-23-000044 · wf-form4_168933932048702.xml · derivative · entry 1 Takahashi Takeshi · CIK 0001963933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2033-02-09 F1 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 02:03 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 44,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001628280-23-003429 · wf-form4_167634016642512.xml · derivative · entry 1 Takahashi Takeshi · CIK 0001963933 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2033-02-09 F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.